Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma

NCT04649060 is registered in ClinicalTrials.gov with Oncopeptides AB as lead sponsor.

NCT NCT04649060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04649060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
Lead sponsor
Oncopeptides AB
Phase
Phase 3
Overall status
Terminated
Start date
December 21, 2020
Completion date
February 7, 2022
Enrollment
54 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed multiple myeloma, relapsed-refractory multiple myeloma